Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Reaffirmed as “Buy” by BTIG Research

Tiziana Life Sciences (NASDAQ:TLSA)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research report issued to clients and investors on Tuesday, Benzinga reports.

TLSA has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, August 26th. Zacks Research raised shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold”.

Tiziana Life Sciences Stock Down 2.9%

TLSA stock traded down $0.03 during mid-day trading on Tuesday, reaching $0.98. 389,012 shares of the stock traded hands, compared to its average volume of 611,348. Tiziana Life Sciences has a 52 week low of $0.76 and a 52 week high of $2.33. The business has a 50-day moving average of $1.00 and a two-hundred day moving average of $1.18.

Insider Transactions at Tiziana Life Sciences

In other Tiziana Life Sciences news, CEO Ivor Elrifi purchased 667,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $1.00 per share, with a total value of $667,000.00. Following the completion of the transaction, the chief executive officer directly owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This trade represents a 17.53% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 988,423 shares of company stock valued at $985,909 over the last three months. Corporate insiders own 39.82% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. purchased a new position in Tiziana Life Sciences Ltd (NASDAQ:TLSA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 323,240 shares of the company’s stock, valued at approximately $414,000. Mid American Wealth Advisory Group Inc. owned approximately 0.25% of Tiziana Life Sciences as of its most recent SEC filing.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer’s disease.